Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients

Autor: Masahiro Imamura, Yasuyuki Kunieda, Tomomi Toubai, Hajime Kobayashi, Masaharu Kasai, Satoshi Hashino, Mitsutoshi Kurosawa, Yasutaka Kakinoki, Junji Tanaka, Tsugumichi Kawamura, Masanobu Morioka, Takashi Fukuhara, Nobuo Masauzi, Masahiro Asaka, Shuichi Ota, Yusuke Shono, Takeshi Kondo
Rok vydání: 2006
Předmět:
Adult
Male
medicine.medical_specialty
Lymphoma
B-Cell
Time Factors
medicine.medical_treatment
Down-Regulation
G-CSF
Disease-Free Survival
491.65
Predictive Value of Tests
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Granulocyte Colony-Stimulating Factor
Biomarkers
Tumor
Humans
Medicine
IL-12 p40
Cyclophosphamide
Survival rate
B cell
Aged
Neoplasm Staging
Aged
80 and over
Chemotherapy
IL-12 p35
Gene Expression Regulation
Leukemic
Interleukin-12 Subunit p40
business.industry
Interleukin
Hematology
General Medicine
Middle Aged
non-Hodgkin’s lymphoma
medicine.disease
Recombinant Proteins
Lymphoma
Granulocyte colony-stimulating factor
Non-Hodgkin's lymphoma
Survival Rate
Endocrinology
medicine.anatomical_structure
Cytokine
Doxorubicin
Vincristine
IL-12
Prednisone
Female
business
Zdroj: European Journal of Haematology. 77:403-409
ISSN: 1600-0609
0902-4441
DOI: 10.1111/j.1600-0609.2006.00746.x
Popis: Interleukin (IL)-12 is a 70-kDa cytokine comprised of two disulfide-linked proteins (p35 and p40) and is essential for the initiation of effective immune response. Granulocyte-colony stimulating factor (G-CSF) affects the balance in the production of anti-inflammatory cytokines. We investigated the serum IL-12 p40 and IL-12 Mix (p40 and p70) production in 28 patients with B-cell lineage non-Hodgkin's lymphoma (NHL) treated with chemotherapy (e.g., CHOP regimen) with or without G-CSF administration and eight healthy volunteers. We found that serum levels of IL-12 p40 (191.2 +/- 150.0 pg/mL) and IL-12 Mix (277.4 +/- 274.5 pg/mL) in the patients before chemotherapy were higher than those in the healthy volunteers (IL-12 p40: 76.4 +/- 25.3 pg/mL, IL-12 Mix: 48.5 +/- 33.4 pg/mL) (P = 0.04 and 0.02, respectively). Next, we examined the serum IL-12 p40 and IL-12 Mix levels in nine patients receiving chemotherapy with administration of G-CSF (CG group, n = 9) and without G-CSF (C group, n = 9). Serum IL-12 p40 and IL-12 Mix levels were decreased on 10 d after chemotherapy in both groups, and those in CG groups were significantly lower than those in C group. These results indicated that administration of G-CSF decreased serum IL-12 p40 and IL-12 Mix levels. Overall survival (OS) at 24 months was not significantly different in the two groups (58.3% in group C vs. 80.0% in group CG, P = 0.67). However, the survival rate of patients at clinical stages III and IV in CG group (n = 6, 66.0%) was significantly better than that of patients in C group (n = 4, 25.0%) (P = 0.02). Long-term administration of G-CSF appears to influence the survival rate by reducing immunosuppressive IL-12 p40 production.
Databáze: OpenAIRE
Externí odkaz: